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Abstract
Background. Antagonists of relevant Gs protein-coupled
and agonists of relevant Gi protein-coupled receptors lower
renal cAMP and inhibit growth of renal cysts in ani-
mal models of human ARPKD (PCK rat) and/or ADPKD
(Pkd2−/WS25 mouse). A calcium-sensing receptor (CaR) is
expressed in various tubular segments and couples to Gq,
thereby activating phospholipase Cγ, InsP3 generation and
calcium mobilization from intracellular stores, and Gi pro-
teins. By both mechanisms, CaR activation could lower
intracellular cAMP and inhibit renal cyst growth.
Methods. PCK rat and Pkd2−/WS25 mouse littermates were
fed rodent chow without or with R-568, a type 2 cal-
cimimetic, at a concentration of 0.05% or 0.1% between
3 and 10 or 16 weeks of age. Histomorphometric analysis
was performed with Meta-Morph software. Western anal-
ysis and immunohistochemical staining were performed
using antibodies for aquaporin-2, urea transporter UT-A1
and CaR. Northern blot hybridization was used to quantify
the expression of vasopressin V2 receptor and aquaporin
2 mRNAs. Cyclic AMP was measured using an enzyme
immunoassay kit.
Results.R-568hadnoeffectonkidneyweight,cystvolume,
plasma BUN concentration or severity of the polycystic
liver disease. A significant reduction in renal interstitial fi-
brosiswasdetectedinPCKrats,butnotinPkd2−/WS25 mice.
R-568 administration, as anticipated, resulted in hypocal-
cemia and hyperphosphatemia, and significant increases in
urine output, osmolar clearance, and urinary excretions of
sodium, potassium and calcium.
Conclusions. CaR activation had no detectable effect on
cystogenesis in models of autosomal recessive or domi-
nantpolycystickidneydisease.Thelackofprotectiveeffect
could be due to the absence of CaR in the outer medullary
and cortical collecting ducts, the reduction in extracellular
calcium and the unaffected levels of renal cAMP and renal
expression of cAMP-dependent genes. A possible benefi-
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cial effect on interstitial fibrosis deserves further study at
more advanced stages of the disease.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD)
and autosomal recessive polycystic kidney disease
(ARPKD) are important causes of ESRD, morbidity and
mortality in children and adults [1,2]. ADPKD is genet-
ically heterogeneous with two disease loci, PKD1 and
PKD2. ARPKD is caused by mutations at a single locus,
PKHD1 [3]. The cysts in ARPKD derive mostly from the
collecting ducts. The cysts in ADPKD may derive from any
tubularsegment,butthedistalnephronandcollectingducts
are predominantly involved.
The PKD1- and PKD2-encoded proteins, polycystin-1
and -2, and the PKHD1-encoded protein, fibrocystin, are
membrane-associated glycoproteins. Polycystin-1 and fi-
brocystin are receptors for unknown ligands and may un-
dergo regulated intramembrane proteolysis. Polycystin-2 is
a calcium permeable cation channel. Polycystin-1 directly
and fibrocystin indirectly interact with polycystin-2 and
regulateitschannelfunction.Polycystin-1,polycystin-2and
fibrocystin are localized to primary cilia [4–7] and are re-
quired for the rise in intracellular calcium triggered by me-
chanical stimulation of these organelles [6,8,9]. Polycystin-
2 is also found in the endoplasmic reticulum, functionally
interacts with inositol 1,4,5-triphosphate (InsP3) and ryan-
odine receptors, and modulates intracellular calcium sig-
naling [10,11].
Alterations in two major interacting second messengers,
intracellular calcium and adenosine 3 ,5 -cyclic monophos-
phate (cAMP) play a role in the pathogenesis of poly-
cystic kidney disease. Cyclic AMP levels reflect a bal-
ance between synthesis by adenylyl cyclases (activated
by Gs protein-coupled, GsPCR, and inhibited by Gi
protein-coupled, GiPCR, receptors) and degradation by
C   The Author [2008].
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version
of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed
as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or
as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.orgR-568 in PCK rats and Pkd2−/WS25 mice 527
phosphodiesterases[12].Stimulationofcalciuminhibitable
adenylyl cyclases and inhibition of calcium-dependent
cAMP phosphodiesterases may account for increased re-
nal levels of cAMP and increased expression of cAMP-
dependent genes in various animal models of polycystic
kidney disease [13–15]. Cyclic AMP stimulates tubular
cells beyond the loop of Henle to secrete chloride and fluid
[16]. In addition, cAMP stimulates mitogen-activated pro-
tein kinase and extracellularly regulated kinase signaling
and cell proliferation in renal epithelial cells of patients
with polycystic kidney disease, whereas it has an inhibitory
effect in wild-type cells [17,18]. This abnormal prolifera-
tiveresponseislinkedtoalterationsinintracellularcalcium
since it can be reproduced in wild-type cells by lowering
intracellular calcium [19]. Conversely, calcium ionophores
or channel activators rescue the abnormal response of cyst-
derived cells [20].
Recently, antagonists of relevant GsPCR (vasopressin
V2 receptor antagonists OPC31260 and OPC41061) or ag-
onists of relevant GiPCR (octreotide) have been shown to
lower renal cAMP [14,15,21,22] and inhibit the develop-
ment and progression of the renal cystic disease in animal
models orthologous to human ADPKD and/or ARPKD.
Type 2 calcimimetic drugs act as selective allosteric modu-
lators of calcium action at the level of the calcium-sensing
receptor (CaR) [23,24]. CaR, a member of subfamily C of
the GPCR superfamily, is capable of coupling to Gq (acti-
vating phospholipase Cγ, InsP3 generation and mobiliza-
tion of calcium from intracellular stores) and Gi proteins,
lowering intracellular cAMP and inhibiting cAMP signal-
ing [25]. Since CaR is expressed in many tubular segments
(apicalmembraneoftheproximaltubule;basolateralmem-
brane of the medullary thick ascending limb, cortical thick
ascending limb and distal convoluted tubules; and apical
surface of the inner medullary collecting duct) [26], we de-
cided to ascertain whether activation of CaR by a type 2
calcimimetic drug would attenuate or prevent the develop-
ment of polycystic kidney disease.
Subjects and methods
Experimental animals and study design
Colonies of PCK rats and of Pkd2+/− and Pkd2WS25/WS25
mice have been maintained in the Animal Facilities of the
Department of Veterinary Medicine at the Mayo Clinic,
Rochester, MN, since 1999. The PCK rat is a model of
human ARPKD caused by a splicing mutation (IVS35–
2A→T) that skips exon 36 and leads to a frameshift in
the ortholog, Pkhd1.T h ePkd2-null mutation was gener-
ated by disrupting the wild-type exon 1 of the Pkd2 with
a selectable neocassette that introduces an in-frame stop
codon.TheWS25mutationwasgeneratedbytheintegration
of an exon 1 disrupted by the introduction of a selectable
neocassette into the first intron of Pkd2 without replac-
ing the wild-type exon 1. This causes an increased rate of
somatic mutations in the Pkd2 gene (intragenic homolo-
gous recombinations between tandemly repeated portions
of the wild-type and mutant exon 1). We crossed Pkd2+/−
and Pkd2WS25/WS25 mice to generate Pkd2−/WS25 mice. We
used these double heterozygote mice because, unlike other
Pkd1+/− orPkd2+/− models,theyreliablydevelopaslowly
progressive renal cystic disease that greatly resembles hu-
man ADPKD. At the time of weaning or 3 weeks of age,
PCK rat and Pkd2−/WS25 mouse littermates were divided
into three groups of 10 male and 10 female animals each
receiving a standard ground rodent chow (Teklad 7017,
Madison WI, USA) or the same chow containing R-568
at a concentration of 0.1% and 0.05 %, estimated to pro-
vide a daily dose of 50 and 25 mg/kg body weight, re-
spectively. Rats were euthanized at 10 weeks and mice at
16 weeks of age, times by which, in our experience, the
disease has developed consistently in the absence of treat-
ment. Tail-cuff blood pressures and 24-h urine collections
inmetaboliccagesfordeterminationofurineoutput,osmo-
lalityand urinary excretions of sodium, potassium, calcium
and phosphorus were obtained weekly on three consecutive
weeks before killing at 10 or 16 weeks of age. At killing,
the animals were weighed and anesthetized with ketamine
(50 mg/kg, rats; 60 mg/kg, mice) and xylazine (10 mg/kg),
intraperitoneally. Blood was obtained by cardiac puncture
for determination of plasma BUN, electrolytes, osmolality,
calcium and phosphorus. The right kidney and part of the
liver were placed into pre-weighed vials containing 10%
formaldehyde in a phosphate buffer (pH 7.4). These tissues
were embedded in paraffin for histological studies. The left
kidney and part of the liver were immediately frozen in liq-
uid nitrogen for determination of cyclic AMP and Western
and Northern blot analysis.
Histomorphometric analysis
Whole 4 µm transverse tissue sections stained with
hematoxylin-eosin and with picrosirius red were used to
measure cyst volumes and fibrosis, respectively. Image
analysisprocedureswereperformedwithMeta-Morphsoft-
ware (Universal Imaging, West Chester, PA, USA). The
Meta-Morph software system includes a light microscope
with a color digital camera (Nikon DXM 1200) and a Pen-
tium IBM-compatible computer (Dell OptiPlex). Stained
sections are visualized under a Nikon microscope and digi-
tal images are acquired using a high-resolution Nikon Dig-
ital camera and displayed on the monitor. The observer in-
teractively applies techniques of enhancement for a better
definition of interested structures and to exclude fields too
damaged to be analyzed. A colored threshold is applied at a
level that separates cysts from non-cystic tissue in order to
calculate cyst volumes. Areas of interest are expressed as a
percentage of total tissue. All the histomorphometric anal-
yses were performed blindly, without knowledge of group
assignment.
Western blot analysis and immunohistochemistry
Western analysis and immunohistochemical staining were
performed using antibodies for aquaporin-2 (Santa Cruz
Biotechnology, Santa Cruz, California), urea transporter
UT-A1 (gift from Dr Jeff M. Sands, Emory University
School of Medicine, Atlanta, GA, USA) and CaR (Abcam
Inc., Cambridge, MA, USA).528 X. Wang et al.
Table 1. Effect of R-568 on the development of polycystic kidney disease in PCK rats
Male Female P value
Control 0.05% 0.1% Control 0.05% 0.1% Gender R-568
(n = 10) (n = 10) (n = 10) (n = 10) (n = 10) (n = 10)
Body weight (g) 340 ± 19 330 ± 20 299 ± 27∗ 234 ± 10 221 ± 15∗ 218 ± 10∗ < 0.001 < 0.001
Kidney weight (% BW) 1.97 ± 0.30 1.95 ± 0.20 1.85 ± 0.21 1.57 ± 0.26 1.61 ± 0.20 1.63 ± 0.20 < 0.001 NS
Kidney cyst volume (%) 22.7 ± 5.4 20.2 ± 5.5 20.9 ± 2.3 21.1 ± 5.6 19.3 ± 6.3 18.9 ± 4.0 NS NS
Kidney fibrosis volume (%) 4.53 ± 1.71 2.17 ± 0.92∗ 1.58 ± 0.41∗ 2.94 ± 1.17 1.28 ± 0.57∗ 1.03 ± 0.41∗ < 0.001 < 0.001
Kidney cAMP (pmol/mg protein) 25.2 ± 8.9 36.6 ± 12.1 33.9 ± 16.7 20.8 ± 10.0 19.3 ± 5.6 17.0 ± 2.7 < 0.001 NS
Plasma BUN (mg/dL) 16.1 ± 1.7 16.7 ± 2.0 20.3 ± 4.6∗ 16.4 ± 0.8 16.9 ± 2.2 16.3 ± 1.6 NS 0.031
Plasma osmolality (mosm/L) 310 ± 10 310 ± 14 306 ± 16 318 ± 13 309 ± 10 310 ± 8N S N S
Plasma phosphorus (mg/dL) 8.4 ± 1.0 10.4 ± 1.5∗ 12.5 ± 1.4∗ 7.4 ± 0.7 9.9 ± 1.3∗ 11.1 ± 0.9∗ 0.003 < 0.001
Plasma calcium (mg/dL) 10.3 ± 0.4 8.4 ± 0.4∗ 8.1 ± 0.5∗ 10.6 ± 0.2 8.6 ± 0.4∗ 8.1 ± 0.2∗ 0.025 < 0.001
Urine volume (µL/min) 8.3 ± 2.4 14.2 ± 2.0∗ 13.5 ± 1.6∗ 4.0 ± 0.5 10.0 ± 2.0∗ 10.1 ± 1.5∗ < 0.001 < 0.001
Urine osmolality (mosm/L) 869 ± 391 863 ± 413 1064 ± 420 1785 ± 577 1795 ± 523 1840 ± 352 < 0.001 NS
Osmolar clearance (µL/min) 21.3 ± 7.9 38.7 ± 17.3∗ 48.1 ± 21.6∗ 22.3 ± 7.9 55.6 ± 11.4∗ 60.0 ± 14.5∗ 0.009 < 0.001
Free water clearance (µL/min) −13.0 ± 9.4 −24.4 ± 17.9 −34.6 ± 20.5∗ −18.3 ± 7.7 −45.6 ± 12.2∗ −49.9 ± 13.8∗ < 0.001 < 0.001
Urine sodium (mEq/24 h) 0.56 ± 0.22 3.03 ± 0.37∗ 2.54 ± 0.88∗ 0.42 ± 0.15 2.02 ± 0.48∗ 2.22 ± 0.54∗ < 0.001 < 0.001
Urine potassium (mEq/24 h) 2.02 ± 0.71 5.44 ± 0.86∗ 5.01 ± 0.85∗ 1.43 ± 0.29 3.58 ± 0.93∗ 4.28 ± 0.99∗ < 0.001 < 0.001
Urine phosphorus (mg/24 h) 18.2 ± 8.4 13.5 ± 4.2 8.6 ± 7.7∗ 13.8 ± 4.2 8.5 ± 4.8∗ 9.0 ± 1.7∗ NS 0.002
Urine calcium (mg/24 h) 1.04 ± 0.63 2.27 ± 0.87∗ 5.48 ± 2.00∗ 0.79 ± 0.41 3.02 ± 0.95∗ 4.30 ± 0.92∗ NS < 0.001
∗P < 0.01 versus control.
Table 2. Effect of R-568 on the development of polycystic kidney disease in Pkd2−/WS25 mice
Male Female P value
Control 0.05% 0.1% Control 0.05% 0.1% Gender R-568
(n = 9) (n = 10) (n = 10) (n = 7) (n = 8) (n = 8)
Body weight (g) 28.4 ± 2.8 27.1 ± 1.1 26.1 ± 2.0 22.4 ± 1.4 22.0 ± 1.7 21.2 ± 1.5 < 0.001 0.027
Kidney weight (%BW) 1.94 ± 0.76 1.60 ± 0.46 1.77 ± 0.62 1.65 ± 0.32 1.45 ± 0.25 1.82 ± 0.85 NS NS
Kidney cyst volume (%) 21.3 ± 17.8 11.0 ± 18.6 16.0 ± 17.1 26.0 ± 11.8 17.8 ± 16.8 22.3 ± 16.4 NS NS
Kidney fibrosis volume (%) 2.44 ± 1.61 1.74 ± 1.68 3.07 ± 3.05 3.13 ± 2.16 1.98 ± 1.91 3.40 ± 3.26 NS NS
Kidney cAMP (pmol/mg protein) 5.90 ± 2.21 5.75 ± 1.82 5.85 ± 2.20 7.04 ± 1.67 7.24 ± 2.17 6.50 ± 3.71 NS NS
Plasma.BUN (mg/dL) 31.1 ± 3.4 29.0 ± 4.2 29.2 ± 6.6 30.2 ± 7.7 28.9 ± 5.0 28.0 ± 4.0 NS NS
Plasma osmolality (mosm/L) 317 ± 11 320 ± 10 319 ± 9 319 ± 10 319 ± 10 319 ± 11 NS NS
Plasma phosphorus (mg/dL) 7.55 ± 0.72 8.25 ± 0.77 8.58 ± 0.95 7.25 ± 1.42 7.63 ± 0.71 7.87 ± 1.02 NS NS
Plasma calcium (mg/dL) 8.53 ± 0.56 7.95 ± 0.67 7.30 ± 0.89∗ 7.63 ± 0.74 7.37 ± 0.82 6.68 ± 1.21∗ 0.009 0.004
Urine volume (µL/min) 0.56 ± 0.48 1.01 ± 0.53 0.72 ± 0.22 0.32 ± 0.22 0.80 ± 0.37∗ 0.52 ± 0.54 NS 0.013
Urine osmolality (mosm/L) 898 ± 265 1076 ± 339 936 ± 288 1514 ± 752 835 ± 333 885 ± 418 NS NS
Osmolar clearance (µl/min) 1.60 ± 1.37 3.28 ± 1.84∗ 2.22 ± 1.26 1.35 ± 0.67 2.20 ± 1.24 1.47 ± 1.46 NS 0.044
Free water clearance (µl/min) −1.04 ± 0.92 −2.26 ± 1.45∗ −1.51 ± 1.08 −1.03 ± 0.59 −1.40 ± 0.97 −0.95 ± 0.96 NS NS
Urine sodium (mEq/24 h) 0.13 ± 0.07 0.23 ± 0.11∗ 0.20 ± 0.06∗ 0.10 ± 0.06 0.25 ± 0.07∗ 0.22 ± 0.17 NS 0.004
Urine potassium (mEq/24 h) 0.15 ± 0.07 0.32 ± 0.18∗ 0.23 ± 0.08∗ 0.11 ± 0.04 0.30 ± 0.08∗ 0.28 ± 0.22 NS 0.003
Urine phosphorus (mg/24 h) 0.85 ± 0.98 2.32 ± 1.32∗ 1.17 ± 0.88 0.84 ± 0.49 1.58 ± 0.91 0.96 ± 1.11 NS 0.009
Urine calcium (mg/24 h) 0.07 ± 0.04 0.08 ± 0.03 0.06 ± 0.03 0.03 ± 0.02 0.07 ± 0.04∗ 0.07 ± 0.05 NS NS
∗P < 0.01 versus control.
Renal expression of vasopressin V2 receptor and
aquaporin 2 mRNAs
Total RNA extracted from wild-type and cystic kidney
pairs using TRIzol reagent (Invitrogen, Carlsbad, CA)
was analyzed by northern blot hybridization using
formaldehyde–agarose gel electrophoresis with transfer of
RNA to nylon membranes. 32P-labeled probes to vaso-
pressin V2 receptor and aquaporin 2 were used and the
hybridized blots were exposed to X-ray film to obtain au-
toradiographs. Autoradiographs of hybridized blots
werescannedandafterbackground wassubtractedandcor-
rectedforRNAloading,thepixeldensityofthebandwasdi-
vided by that of an internal control (L32) providing mRNA
expression normalized to L32.
Cyclic AMP content of whole kidneys
The kidneys were ground to fine powder under liquid
nitrogen in a stainless steel mortar and homogenized in
10volumesofcold5%TCAinaglass-Teflontissuegrinder.
After centrifugation at 600 g for 10 min, the supernatants
were extracted with three volumes of water-saturated ether.R-568 in PCK rats and Pkd2−/WS25 mice 529
Fig. 1. Renal expression (Western blots) of aquaporin 2 and urea transporter UT-A1 in male and female PCK rats on no treatment (white bars) or
treated with 0.05% (gray bars) or 0.1% (black bars) R-568 added to their diet. ∗P < 0.05 versus no treatment.
Fig. 2. Renal expression (Western blots) of aquaporin 2 and urea transporter UT-A1 in male and female Pkd2−/WS25 mice on no treatment (white bars)
or treated with 0.05% (gray bars) or 0.1% (black bars) R-568 added to their diet. ∗P < 0.05 versus no treatment.530 X. Wang et al.
Fig. 3. Renal expression (Northern blots) of aquaporin 2 and vasopressin V2 receptor mRNA in male and female PCK rats on no treatment (white
bars) or treated with 0.05% (gray bars) or 0.1% (black bars) R-568 added to their diet. ∗P < 0.05 versus no treatment.
Fig. 4. Renal expression (Northern blots) of aquaporin 2 and vasopressin V2 receptor mRNA in male and female Pkd2−/WS25 mice on no treatment
(white bars) or treated with 0.05% (gray bars) or 0.1% (black bars) R-568 added to their diet. ∗†P < 0.01 versus no treatment.
After drying the aqueous extracts, the reconstituted sam-
ples were processed without acetylation using an en-
zyme immunoassay kit (Sigma-Aldrich, Inc., St. Louis,
MO, USA). The results were expressed in pmol/mg of
protein.
Chemical determinations
Plasma blood urea nitrogen (BUN), phosphorus, calcium
and electrolytes were measured with a Hitachi Modular
System. Urine phosphorus, calcium and electrolytes were
measured using a Hitachi 912 analyzer and Perkin-Elmer
Optima2100DVinstrument,respectively.Plasmaandurine
osmolalities were measured using a computerized micro-
osmometer.
Statistical methods
Comparisons between groups were made using two-
way analysis of variance (ANOVA) with least significantR-568 in PCK rats and Pkd2−/WS25 mice 531
Fig. 5. Representative kidney sections from male and female PCK rats (panel A) and Pkd2−/WS25 mice (panel B) on no treatment or treated with 0.05%
or 0.1% R-568 added to their diet.
difference comparisons of the means. Data are expressed
as means ± SD.
Results
The administration of R-568 to PCK rats (Table 1) and
Pkd2−/WS25 mice (Table 2) was accompanied by a small
but significant reduction in body weight, but it was oth-
erwise well tolerated without apparent toxicity. In both
animal models, it induced a reduction in serum calcium
and an increase in serum phosphorus, which were accom-
panied in PCK rats by an increase in the urinary excre-
tion of calcium and a reduction in the urinary excretion of
phosphorus.
The administration of R-568 also resulted in a signifi-
cantincreaseinurineoutput,osmolarclearanceandurinary
excretions of sodium and potassium in both rats and mice,
without significant changes in plasma or urine osmolality
(Tables 1 and 2). The increase in urine output was accom-
panied by a significant reduction in the renal aquaporin-2
protein in both animal models (Figures 1 and 2). The lev-
els of cAMP (Tables 1 and 2) and mRNA expression of
aquaporin-2 were not affected significantly by R-568 ad-
ministration (Figures 3 and 4). Female PCK rats treated
with the lower R-568 dose had a higher expression of the
UT-A1 protein than control rats or those treated with the
higher dose and male rats treated with the higher R-568
dose had an increased expression of V2R mRNA compared
to controls (Figures 1–4).
Despite the expected pharmacologic effects (hypocal-
cemia and hyperphosphatemia, increased urine output and
osmolar clearance), R-568 had no significant effect on
the development of polycystic kidney disease in PCK rats
and Pkd2−/WS25 mice as reflected by kidney weights, cyst
volumes and plasma BUN concentration (Tables 1 and 2
Figure 5). The majority of cysts in both animal models did
not stain with the CaR antibodies (Figure 6). A significant
reduction in interstitial fibrosis was detected in PCK rats
thatappearedtobedosedependent(Table1);inPkd2−/WS25
mice, however, a significant effect on fibrosis was not ob-
served. Liver weights, cyst and fibrosis volumes were also
similar in control and treated PCK rats and Pkd2−/WS25
mice (results not shown).532 X. Wang et al.
Fig. 6. Immunohistochemical staining of kidney sections from PCK rats (panel A) and Pkd2−/WS25 mice (panel B) with a CaR antibody. Most cells
lining the cysts show no staining. ×100, insets ×400.R-568 in PCK rats and Pkd2−/WS25 mice 533
Discussion
The administration of R-568 did not have a significant
effect on cyst growth in two different models of PKD
although it had pharmacologic effects on renal function
and mineral metabolism [27]. The hypercalciuric effect of
R-568 (Tables 1 and 2) is due to the activation of the CaR
in the thick ascending limb of Henle and distal convoluted
tubule. In the thick ascending limb of Henle, activation
of the CaR inhibits calcium reabsorption by two mecha-
nisms. The first is by eliciting phospholipase A2 (PLA2)-
mediated arachidonic acid release and production of
20-hydroxyeicosatetraenoic acid that inhibits the apical
potassium channel Kir1.1 (ROMK) [28,29]. ROMK is nec-
essary for the recycling of potassium, sustained reabsorp-
tionofsodiumchlorideviatheNa–K–2Clcotransporterand
passive paracellular reabsorption of calcium in the thick
ascending limb of Henle. The second mechanism is by
inhibiting the vasopressin-dependent stimulation of adeny-
lyl cyclase and downregulation of the Na–K–2Cl cotrans-
porter expression [30]. It should be noted that a marked
hypercalciuric effect of R-568 was observed only in the
PCK rat (see below). The hypophosphaturic effect in the
PCK rat (Table 1) is consistent with the inhibition of
parathyroid hormone secretion and with the calcimimetic-
induced blunting of the phosphaturic action of parathy-
roid hormone in the proximal tubule. Most likely, the hy-
perphosphatemic and hypocalcemic effects of R-568 are
directly due to the inhibition of parathyroid hormone se-
cretion and to a large extent independent of the observed
hypercalciuric and hypophosphaturic effects (Tables 1 and
2)sincetheycanalsobeobservedintotallynephrectomized
animals [31].
Polyuria, as it occurred in this study, is also a known cal-
cimimetic effect. It has been attributed to the disruption of
urinary concentration by its action on the basolateral CaR
in the thick ascending limb of Henle (inhibition of sodium
chloridereabsorptionanddisruptionofcountercurrentmul-
tiplication mechanism) and on the apical CaR in the inner
medullary collecting duct (inhibition of the vasopressin-
induced effect on water permeability) [32,33]. Indeed, the
administration of R-568 resulted in a significant reduc-
tion in the aquaporin-2 protein (Figures 1 and 2). As pre-
viously described in chronic hypercalcemic/hypercalciuric
rats [32,33], the reduction in the aquaporin-2 protein was
likelyduetoincreaseddegradationratherthanreducedsyn-
thesis since it occurred without a reduction in aquaporin-2
mRNA (Figures 3, 4). Moreover, renal cAMP levels were
not affected by R-568. Female PCK rats treated with the
lower R-568 dose had a higher expression of the UT-A1
protein than control rats or those treated with the higher
dose, and male rats treated with the higher dose had an in-
creasedexpressionofV2RmRNA.Theseobservationsmay
point to dose-dependent effects that we have not explored
fully. The calcimimetic-induced polyuria in our study was
accompanied by a significant increase in osmolar clear-
ance and urinary excretion of sodium, potassium and cal-
cium. Therefore reduced expression or apical targeting of
aquaporin-2 cannot entirely explain the increase in urine
volume.
Despite the observation of the expected pharmacologic
effects on renal function and mineral metabolism, R-568
had no significant effect on kidney cyst volume in PCK
rats and Pkd2−/WS25 mice (Tables 1 and 2). There are at
leastthreepossibleexplanationsforthislackofeffect.First,
CaR is not significantly expressed in the outer medullary
and cortical collecting ducts [26], the main site of cyst de-
velopment in the PCK rat and Pkd2−/WS25 mice [34]; this is
consistent with the observation that most cysts did not stain
with CaR antibodies. A recent study showing that CaR is
expressed in mouse cortical collecting duct cell line (mp-
kCCDcl4) [35] makes this explanation less likely. Second,
the administration of R-568 resulted in hypocalcemia and
therefore it is possible that the effects of R-568 on intra-
cellular calcium and cAMP are negated by the reduction in
extracellular calcium. Lowering extracellular calcium has
beenshowntoinduceaphenotypicswitchfromwildtypeto
polycystic [19]. It has also been shown to increase cAMP
in rat collecting duct cells [36] and in vascular smooth
muscle cells freshly dissected from PKD2WS25/− mice
[37]. Third, the inhibition of the vasopressin elicited wa-
ter permeability induced by the effect of high urinary cal-
cium on the apical CaR in the inner medullary collecting
duct may occur despite a fully functional adenylyl cyclase,
as suggested by the fact that in models of chronic hyper-
calcemia vasopressin elicits increases in urea permeabil-
ity [33] regulated through increases in intracellular cAMP
[38]. Consistent with the last two explanations, the renal
cAMP levels (Tables 1 and 2) and the expressions of the
urea transporter UT-A1 protein and of vasopressin V2 re-
ceptor mRNA (Figures 1–4) in the treated PCK rats and
Pkd2−/WS25 mice were similar to or higher than those in
the control animals. The administration of R-568 had no
significant effect on the development of polycystic liver
disease in either animal model. This is consistent with
the lack of expression of CaR in the biliary epithelium
[39].
The extent of renal interstitial fibrosis in PCK rats and
Pkd2−/WS25 mice at the ages evaluated in our study was
modest. The administration of R-568 significantly reduced
the extent of the renal fibrosis in the PCK rat, but it had no
effectonrenalfibrosisinPkd2−/WS25 miceoronliverfibro-
sisineithermodel.Thiscouldreflectthatintherattherenal
effects of R-568 are more robust as reflected by its greater
effect on urinary calcium excretion. In addition, there may
be a species difference since renal fibrosis may be easier
to induce in rats than in mice. While the mechanism and
significance of the favorable effect on interstitial fibrosis
in PCK rats is uncertain, it must be noted that R-568 has
been reported to ameliorate the tubulo-interstitial damage
in subtotally nephrectomized rats, possibly by reducing the
levels of parathyroid hormone [36]. This antifibrotic ef-
fect of calcimimetic therapy may have a therapeutic action
that may deserve further study at more advanced stages of
polycystic kidney disease.
In summary, despite a sound rationale for considering
calcimimetics in the treatment of polycystic kidney dis-
ease, their administration failed to ameliorate the cystic
growth in animal models orthologous to human ARPKD
and ADPKD.534 X. Wang et al.
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